ClinicalTrials.gg
RecruitingNCT02902198Updated Apr 3, 2025

Taste Physiology in Obese Volunteers Before and After Bariatric Surgery

An interventional study of Placebo and Glucose in Obesity, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Dec 2014, registered Sep 2016).
  • Started Dec 2014; still recruiting 11 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies testing glucose in Obesity — 3 open to participants now, 3 under way, none of them phase 3. Glucose · Obesity.

Planned enrollment
15th of 17
16 · median 20
Started
2014
the only one that year
No phase
12 of 17
2 open now
Registered
7th of 17
by date

Among the 17 studies testing glucose in Obesity, this one is the 15th largest by planned enrollment, is the only one that started in 2014, is one of 12 with no phase, and was the 7th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 17 studies testing glucose in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About glucose

Glucose: first FDA approval 1946 (ALCOHOL 5% AND DEXTROSE 5%). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing glucose in Obesity, or all of them as a file.
02

Study summary

The objective is to investigate neuro-anatomical correlates of gastrointestinal taste stimulation by means of functional MRI before and after bariatric surgery. Intragastric administration of glucose, monosodium glutamate, chloroquine and placebo is followed by functional brain MRI in obese humans before and 3 months after surgery.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • morbidly obese patients ( min 35kg/m2) scheduled for bariatric surgery
  • right handed

Exclusion criteria

Exclusion Criteria:

  • cardiovascular disease
  • neurologic/psychiatric disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
16 participants (estimated)

Study arms

  • Placebo comparator
    Placebo preoperative

    Single intragastric instillation of 200ml tap water via nasogastric tube

    Dietary Supplement: Placebo

  • Placebo comparator
    Placebo postoperative

    Single intragastric instillation of 200ml tap water via nasogastric tube

    Dietary Supplement: Placebo

  • Active comparator
    Glucose preoperative

    Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube

    Dietary Supplement: Glucose

  • Active comparator
    Glucose postoperative

    Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube

    Dietary Supplement: Glucose

  • Active comparator
    Monosodium glutamate preoperative

    Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube

    Dietary Supplement: Monosodium glutamate

  • Active comparator
    Monosodium glutamate postoperative

    Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube

    Dietary Supplement: Monosodium glutamate

  • Active comparator
    Quinine preoperative

    Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube

    Dietary Supplement: Quinine

  • Active comparator
    Quinine postoperative

    Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube

    Dietary Supplement: Quinine

Interventions

  • Dietary supplementPlacebo

    Tap water 200ml

  • Dietary supplementGlucose

    25g Glucose in 200ml tap water

  • Dietary supplementSodium GlutamateStudies of Sodium GlutamateSodium Glutamate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1g monosodium glutamate in 200ml tap water

  • Dietary supplementQuinine

    17mg quinine in 200ml tap water

06

What researchers measure

Primary outcomes

  1. Effect of tastants on cerebral blood flow measured by functional brain MRI

    Time frame: changes from baseline to one hour after treatment

Secondary outcomes

  1. Effect of tastants plasma glucagon-like peptide (GLP-1) concentrations

    Time frame: changes from baseline to one hour after treatment

  2. Effect of tastants plasma ghrelin concentrations

    Time frame: changes from baseline to one hour after treatment

07

Study locations

1 of 1 sites recruiting
  • University Hopital Basel
    Basel, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2014 (actual). Primary completion is estimated for Dec 2026, 144 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 144 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2016
First posted
Sep 15, 2016
StartActual
Dec 2014
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02902198
Responsible party
Sponsor
First posted
Sep 15, 2016
Start date
Dec 2014
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 3, 2025

Study contacts

Bettina Wölnerhanssen, Dr
Contact
bettina.woelnerhanssen@usb.ch
Christoph Beglinger, Prof
study chair · University Basel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glucose · Sodium Glutamate · Quinine

Start the discussion